Company / Operating Income
Ernexa Therapeutics Inc. Operating Income History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$15.7M
FY2025
5-year range
-$33.2M / $203.0K
FY2021-FY2025
Trend
+25.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has fluctuated over the past 10 years, ranging from -$33M in FY2023 to $203,000 in FY2019.
Based on SEC 10-K filings.
-$16M in FY2025.
Improved from -$33M to -$16M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income increased 25.8% year-over-year.
- Peak operating income was recorded in FY2019.
- Lowest operating income in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$15.7M | +25.8% |
| FY2024 | -$21.1M | +36.4% |
| FY2023 | -$33.2M | -1785.2% |
| FY2020 | -$1.8M | -968.0% |
| FY2019 | $203.0K | +114.5% |
| FY2018 | -$1.4M | +38.5% |
| FY2017 | -$2.3M | +67.0% |
| FY2016 | -$6.9M | -45.4% |
| FY2015 | -$4.7M | -323.8% |
| FY2014 | -$1.1M | -5.4% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026